Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
89Zr-βS-hRS7 + 177Lu-βS-hRS7 is a site-specifically glycan-conjugated theranostic pair targeting Trophoblast cell-surface antigen 2 (TROP2). Developed by researchers at Peking University Cancer Hospital & Institute, the theranostic pair consists of the humanized anti-TROP2 monoclonal antibody hRS7 site-specifically conjugated with DFO/DOTA chelators via β-galactosidase and galactosyltransferase, followed by radiolabeling with zirconium-89 (89Zr) for PET/CT imaging or lutetium-177 (177Lu) for targeted radionuclide therapy. In preclinical models of TROP2-positive triple-negative breast cancer (TNBC), the site-specific theranostic pair demonstrated superior TROP2 affinity, tumor targeting, and retention compared to conventional randomly conjugated probes, resulting in improved imaging contrast and enhanced therapeutic efficacy.
| Indication | Highest phase | Status |
|---|---|---|
| triple-negative breast cancer (TNBC) / hormone-receptor-negative, HER2-negative breast cancer (HR-/HER2-) | Preclinical | Active |
Every indication, with countries and timelines, is in the full profile.
| Market | Status | Year |
|---|---|---|
| United States | Not approved | — |
| European Union | Not approved | — |
| China | Not approved | — |
| Japan | Not approved | — |
Approved indications and other markets are in the full profile.
Lead indication: triple-negative breast cancer (TNBC) / hormone-receptor-negative, HER2-negative breast cancer (HR-/HER2-)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 89Zr-βS-hRS7 + 177Lu-βS-hRS7.
Work on 89Zr-βS-hRS7 + 177Lu-βS-hRS7? Claim this page to correct or add information. Claim this page